Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25424805 | 0.89 | ROCK2 (0.40) | ROCK2ROCK1 | |
| SCHEMBL25423833 | 0.87 | MCL1 (0.37) | MCL1ROCK2ROCK1PDK2IRAK4 | |
| SCHEMBL25425745 | 0.86 | ROCK2 (0.35) | MCL1ROCK2ROCK1 | |
| SCHEMBL25423156 | 0.84 | AKT1 (0.39) | ROCK2ROCK1 | |
| SCHEMBL26999128 | 0.83 | MCL1 (0.37) | MCL1ROCK2ROCK1PRKAG1PRKAA2 | |
| SCHEMBL25424012 | 0.83 | MAP3K14 (0.38) | MCL1ROCK2ROCK1RXRARXRB | |
| SCHEMBL26998150 | 0.82 | ROCK2 (0.36) | MCL1ROCK2ROCK1PDK2 | |
| SCHEMBL25422539 | 0.81 | MCL1 (0.33) | MCL1ROCK2ROCK1 | |
| SCHEMBL29039229 | 0.81 | MCL1 (0.35) | MCL1ROCK2ROCK1 | |
| SCHEMBL25425034 | 0.80 | TDO2 (0.39) | MCL1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-10 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-4208452-A1 | QUINOLINE CGAS ANTAGONIST COMPOUNDS | Immunesensor Therapeutics, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-116234802-A | Quinoline CGAS antagonist compounds | 免疫传感器治疗股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| WO-2022051634-A1 | QUINOLINE CGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | MCL1 1487/4885ROCK2 1771/4885ROCK1 2582/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | MCL1 1487/4885ROCK2 1771/4885ROCK1 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.